Today's Breaking News
- First Patient Dosed in Randomised Phase 2 Clinical Trial of MTL-CEBPA in Patients with Advanced Liver Cancer
- Merck Provides U.S. and Japan Regulatory Update for Gefapixant
- Genentech’s Evrysdi (risdiplam) Granted FDA Priority Review for Treatment of Pre-Symptomatic Babies Under 2 Months of Age With Spinal Muscular Atrophy (SMA)
Latest R&D and Business News
- Vyepti[®] (eptinezumab) approved by the EU Commission for the preventive treatment of migraine in adults
- Tango Therapeutics Announces Clearance of TNG908 IND by FDA and Recent Pipeline Progress Updates
- TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-100 for the Treatment of Hematologic Malignancies
- Masonic Cancer Center at the University of Minnesota Receives FDA Clearance to Proceed with Phase 1 Clinical Trial in Solid Tumors for HCW9218, HCW Biologics’ Novel Bifunctional Fusion Protein
- Lyell Immunopharma Announces FDA Clearance of IND for LYL132, a T-Cell Receptor Therapy for Solid Tumors Being Developed in Collaboration with GSK
- RemeGen's Telitacicept Demonstrates Positive Results in Phase II Trial in Treatment of Primary Sjögren's Syndrome
- Samsung Biologics Reports Fourth Quarter & Fiscal Year 2021 Financial Results
- Viking Therapeutics Announces Clinical Hold on Phase 1b Trial of VK0214 in Patients with X-ALD
- BeiGene Announces Positive Findings from Phase 3 Trial of Tislelizumab in Combination with Chemotherapy in First-Line Gastric or Gastroesophageal Junction Cancer
- Bio-Thera Solutions Announces First Patient Dosed in Australia for BAT6021, an ADCC-enhanced Monoclonal Antibody Targeting TIGIT for the Treatment of Solid Tumors
- SQZ Biotechnologies Announces FDA Clearance of Investigational New Drug (IND) Application for SQZ-eAPC-HPV, a Novel mRNA-based Cell Therapy for the Treatment of HPV16 Positive Solid Tumors
- Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2b Pivotal Trial Evaluating HZN-825 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)